Cdk5 activity in donor T cells is primarily responsible for reductions in GVHD
| Group . | GVHD score . | Survival, % . | ||
|---|---|---|---|---|
| Week 4 . | Week 5 . | Week 6 . | ||
| F1 → F1 | 0.2 ± 0.2 | 0.0 ± 0.0 | 0.0 ± 0.0 | 100 |
| Allo WT T + Allo WT BM → F1 | 5.0 ± 0.4 | 5.2 ± 0.5 | 5.8 ± 0.1 | 13 |
| Allo WT T + Allo KO BM → F1 | 4.8 ± 0.6 | 4.6 ± 0.6 | 4.5 ± 0.5 | 33 |
| Allo KO T + Allo KO BM → F1 | 2.4 ± 0.3* | 2.5 ± 0.4* | 3.0 ± 0.5* | 73* |
| Allo KO T + Allo WT BM → F1 | 3.2 ± 0.8* | 2.6 ± 0.5* | 2.7 ± 0.4* | 60* |
| Group . | GVHD score . | Survival, % . | ||
|---|---|---|---|---|
| Week 4 . | Week 5 . | Week 6 . | ||
| F1 → F1 | 0.2 ± 0.2 | 0.0 ± 0.0 | 0.0 ± 0.0 | 100 |
| Allo WT T + Allo WT BM → F1 | 5.0 ± 0.4 | 5.2 ± 0.5 | 5.8 ± 0.1 | 13 |
| Allo WT T + Allo KO BM → F1 | 4.8 ± 0.6 | 4.6 ± 0.6 | 4.5 ± 0.5 | 33 |
| Allo KO T + Allo KO BM → F1 | 2.4 ± 0.3* | 2.5 ± 0.4* | 3.0 ± 0.5* | 73* |
| Allo KO T + Allo WT BM → F1 | 3.2 ± 0.8* | 2.6 ± 0.5* | 2.7 ± 0.4* | 60* |
Lethally irradiated B6D2F1 received HCT from either syngeneic B6D2F1 or allogeneic Cdk5+/+C (Allo WT) or Cdk5−/−C (Allo KO) donors as described in Figure 2. Two additional allogeneic groups were evaluated in this “mixing” experiment as described in “Methods”: allogeneic KO BM cells mixed with allogeneic WT T cells and allogeneic WT BM cells mixed with allogeneic KO T cells. Survival was monitored daily and GVHD clinical scores were assessed weekly as described; n = 8 to 16 per group.
P < .01 compared with recipients of Cdk5+/+C HCT.